Moxifloxacin and torsade de pointes

Annals of Pharmacotherapy

Volumn 41, Issue 2, 2007, Pages 336-340

  Dale, Krista M ^a,b   Lertsburapa, Kirkeith ^b   Kluger, Jeffrey ^b   White, C Michael ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

Moxifloxacin; Torsade de pointes

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; DOXYCYCLINE; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

AGED; ANTIBIOTIC THERAPY; ARTICLE; CASE REPORT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEART ARRHYTHMIA; HUMAN; NARANJO PROBABILITY SCALE; PATIENT MONITORING; PNEUMONIA; POLYMORPHIC VENTRICULAR TACHYCARDIA; PRIORITY JOURNAL; QT INTERVAL; RATING SCALE; RISK FACTOR; SINUS RHYTHM; TORSADE DES POINTES;

AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; QUINOLINES; TORSADES DE POINTES; TREATMENT OUTCOME;

EID: 33847386304     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H474     Document Type: Article

References (17)

1. El-Sherif N, Turitto G. Torsade de pointes. Curr Opin Cardiol 2003;18:6-13.
2. Kay GN, Plumb VJ, Arciniegas JG, Henthorn RW, Waldo AL. Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J Am Coll Cardiol 1983;2:806-17.
3. Amankwa K, Krishnan SC, Tisdale JE. Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors. Clin Pharmacol Ther 2004;75:242-7.
4. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 2001;21:1468-72.
5. Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM. What clinicians should know about the QT interval. JAMA 2003;289:2120-7.
6. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
7. Owens RC. Risk-assessment for antimicrobial agent-induced QTc interval prolongation and torsade de pointes. Pharmacotherapy 2001;21:301-19.
8. White CM, Song JC, Chow MSS. Cardiac arrhythmias. In: Koda-Kimble MA, Young LY, eds. Applied therapeutics: the clinical use of drugs. 8th ed. New York: Lippincott Williams & Wilkins, 2004. 1-20.34.
9. US Food and Drug Administration. Preliminary concept paper on the clinical evaluation of the QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. www.fda.gov/ohrms/dockets/ac/03/ briefing/pubs%5Cprelim.pdf (accessed 2007 Jan 17).
10. Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-QT syndrome: clinical impact. Circulation 2001;103:89-95.
11. Viskin S. Long QT syndromes and torsade de pointes. Lancet 1999;67:774-6.
12. Donger C, Denjoy I, Berthet M, et al. KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation 1997;96:2778-81.
13. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation 1990;81:686-90.
14. Yang T, Roden DM. Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. Circulation 1996;93:407-11.
15. Tran H, White CM, Chow MSS, Kluger J. An evaluation of the impact of gender and age on QT dispersion in healthy subjects. Ann Noninv Electrocardiol 2001;6:129-33.
16. Kluger J, Giedrimiene D, White CM, Verroneau J, Giedrimas E. A comparison of the QT and QTc dispersion among patients with sustained ventricular tachyarrhythmias and different etiologies of heart disease. Ann Noninv Electrocardiol 2001;6:319-22.
17. Schenck JB, Rizvi AA, Lin T. Severe primary hypothyroidism manifesting with torsades de pointes. Am J Med Sci 2006;331:154-6.